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Abstract
Background: Implantation of human multipotent stromal cells from bone marrow (hMSCs) into the dentate gyrus of the
hippocampus of mice was previously shown to stimulate proliferation, migration and neural differentiation of endogenous
neural stem cells. We hypothesized that hMSCs would be beneficial in a mouse model of Huntington disease (HD) due to
these neurogenic effects.
Results: We implanted hMSCs into the striatum of transgenic mice (N171-82Q) that are a model for HD. The implanted
hMSCs rapidly disappeared over 3 to 15 days. However, they increased proliferation and neural differentiation of
endogenous neural stem cells for up to 30 days. They also increased neurotrophic signaling and decreased atrophy of the
striatum in 3-month old HD mice implanted with hMSCs one month earlier.
Conclusions: The results therefore suggested that neural implantation of hMSCs may be of benefit in HD but a number of
parameters of dose, treatment schedule, and route of administration need to be optimized.
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Introduction
HD is an autosomal dominant genetic disorder caused by the
expansion of polyglutamine expeats in Exon 1 of the IT15 gene
encoding for Huntingtin (Htt). The polyglutamine repeat length
determines the age of onset and the overall level of function, but
not the severity of the disease [1]. Although the exact mechanism
underlying HD disease progression remains uncertain, the
hallmark of this disease is gross atrophy of the striatum and
cortex [2]. The average age of onset for HD is 37–38 years [3] and
the median life expectancy after disease onset is 16.2 years (with a
span of 2–45 years). The disease duration is similar regardless of
age of onset [4]. HD is an extremely debilitating disease, affecting
motor, cognition, and psychological stability [5]. According to the
2007 World Congress on HD, there are several clinical trials for
treatments for HD, but there is currently no effective therapy
(http://www.hda.org.uk/congress/index.html).
One strategy for therapy of HD is to enhance neurogenesis.
Neurogenesis is not negatively affected by mutant Htt; in fact, the
number of proliferating progenitor cells and new neurons in the
subventricular zone (SVZ) and surrounding area was increased in
HD patients compared to control [6,7,8,9]. Similarly in the HD
rat model created by quinolinic acid injection, neostriatal
neurogenesis was increased and neuroblasts migrated to the site
of the lesion in the striatum instead of to the olfactory bulb [10]. A
transgenic mouse model for HD also suggested an upregulation of
neurogenesis, but there was no improvement in the HD phenotype
[11]. This natural upregulation of neurogenesis may be further
augmented by administration of fibroblast growth factor (FGF-2)
[12,13], nerve growth factor (NGF) [14,15], and ciliary neuro-
trophic factor (CNTF) [16], thus improving the pathology and/or
phenotype of the disease.
One potential means of increasing neurogenesis in HD is the
administration of stem/progenitor cells. Among the stem/progenitor
cells currently being tested are the adult stem/progenitor cells from
bone marrow referred to initially as fibroblastic colony forming units,
then as marrow stromal cells, subsequently as mesenchymal stem
cells, and most recently as multipotent mesenchymal stromal cells, or
MSCs [17,18]. MSCs are readily obtained from small samples of
bone marrow and expanded in culture. They initially attracted
interest as therapeutic agents because they differentiate into multiple
phenotypes in culture and in vivo [19,20]. Initial observations
indicated that MSCs infused into the lateral ventricles of newborn or
fetal rodents engrafted and probably differentiated into neural cells
[21,22,23]. Subsequent observations, particularly involving adult
animals, indicated that differentiation into neural cells was unlikely to
be a major factor [24,25,26]. Cell fusion and trans-differentiation
may be possible; however, it is unlikely that these completely account
for the therapeutic effects accounted to MSCs [25]. Instead, the cells
promote repair of the CNS by creating a more favorable
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secretion of cytokines and chemokines or other mechanisms
[27,28,29]. In the immunodeficient adult mice, injection of hMSCs
into the dentate gyrus of the hippocampus increased propagation,
migration and neural differentiation of endogenous neural stem cells
[30]. Also, injection of hMSCs into the dentate gyrus of
immunocompetent mice one day after transient global ischemia
improved neurological deficits and decreased neuronal death by the
modulating immune and inflammatory responses of the mouse brain
[31]. In this study, we tested the hypothesis that implantation of
hMSCs into the striatum may have beneficial effects in a transgenic
mouse model for HD. The cells increased neurogenesis and
decreased atrophy of the striatum.
Results
Grafted hMSCs Do Not Survive in the HD Striatum
Previous studies demonstrated that hMSCs implanted into the
dentate gyrus disappeared over 5 to 7 days in both immunode-
ficient and immunocompetent mice [30,31]. To determine
whether implantation of hMSCs would have a similar effect in
a mouse model for HD, 100,000 hMSCs were implanted into the
striatum of 8 wk old mice (HD N171-82Q) and the brains were
e x a m i n e da f t e r1 ,3 ,5 ,7 ,1 5 ,a n d3 0d a y s( n=5 26). Microscopy
for the GFP cells (Figure 1A) at 1 day post-implantation showed
that the MSCs had engrafted. Most of these cells survived for at
least 3 days post-implantation as cells which retained the spindle-
Figure 1. GFP-hMSCs did not survive in the HD striatum. (A) An intact graft of GFP-hMSCs was evident at 1–3 days post-implantation. Only a
few intact cells survived to 5 days and only cell remnants remained for 7–30 days. Squares demarcate location of high magnification inset. Scale
bar=100 mm. (B) Stereological cell counting confirmed only 15.1% of the 100,000 grafted hMSCs survived to 1 day and 17.3% to 3 days. Survival
significantly dropped (n=526; p=0.004) to 4.5 and 3.5% at 5 and 7 days. By 15 days no intact cells were counted. * denotes significance based on
ANOVA and Holms-Sidak as the post-hoc test.
doi:10.1371/journal.pone.0009347.g001
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days post-surgery, the size of the graft was smaller and fewer
GFP-hMSCs were present. By 15 days post-implantation, only
remnants of the GFP-hMSCs, and no intact cells, were found
(Figure S1).
The total number of grafted GFP-hMSCs was also estimated
u s i n gs t e r e o l o g i c a lc o u n t i n g( F i g u r e1 B )o nt h es a m es e c t i o n s
used for the immunostaining. Only intact hMSCs with typical
spindle-shaped morphology were included in this analysis
(Figure 1A, inset images). Of the 100,000 cells that were
implanted in the striatum, only 15.1% survived the first 24 hours
post-operatively (15,06363,776 cells). There was no significant
change at 3 days, with approximately 17.3% of the grafted cells
remaining (17,29363374 cells, p=0.573). The number of
surviving GFP-hMSCs was significantly reduced between 3–5
days post-transplantation, with only 4.5% of the cells remaining
(4,48161678 cells, p=0.004) and about the same number at day
7 (Not Significant change). At 15 and 30 days post-implantation,
intact GFP-hMSCs were not detected.
Grafting hMSCs into the HD Striatum Significantly
Increases Endogenous Cell Proliferation
Previous observations indicated that grafting hMSCs into the
hippocampus of healthy mice increased the proliferation of
endogenous neural cells [30]. To determine whether hMSCs
enhanced the proliferation of endogenous cells in an HD mouse
model, the number of proliferating cells in the SVZ and striatum
was assessed by injecting mice with BrdU every 12 hours for the
first 7 days post-implantation, thus labeling all actively dividing
cells during the first 7 days and slowly proliferating cells from days
7–30. Immunostaining indicated an increase in the number of
BrdU
+ cells in the hMSC-implanted hemisphere within the first
day post-implantation when compared to the PBS-injected,
contralateral hemisphere (Figure 2 A, E). At 3, 5, 7, and 15 days
post-implantation there were still more BrdU
+ cells in the hMSC-
implanted hemisphere than in the contralateral, PBS-injected,
control hemisphere (Figure 2 B–D compared to F–H and I
compared to L). At 30 days post-implantation, there was a marked
decrease in the number of BrdU
+ cells in both hemispheres
Figure 2. Grafting hMSCs increased the proliferation of endogenous cells in the SVZ and striatum. hMSC implantation increased
endogenous cell proliferation at 1-30 days post-implantation (A-D, I-J), but not in the contralateral, PBS-injected hemisphere (E-H, L-M). There was no
increase in cell proliferation after dead hMSCs were implanted into the striatum (K,N). (O) hMSCs increased cell proliferation in the striatum from 1 to
15 days post-transplantation (n=526). There were significantly more dividing, BrdU
+ cells in the hMSC-implanted hemisphere than the PBS-injected
hemisphere at 5–15 days post-implantation. There was no difference in the number of BrdU
+ cells in either hemisphere when dead hMSCs were
implanted. * and a denote p,0.05 by ANOVA with Holms-Sidak post-hoc analysis.
doi:10.1371/journal.pone.0009347.g002
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HD striatum. There was no increase in the number of BrdU
+ cells
in the dead hMSC-implanted hemisphere compared to the
contralateral PBS-injected hemisphere when analyzed by immu-
nostaining at 7 days post-implantation (Figure 2 K, N). At 5 days
post-implantation intact GFP-hMSCs can still be detected;
however, confocal microscopy confirmed that these cells were
not BrdU
+ (P-S).
The number of BrdU
+ cells in each hemisphere was also
counted by stereology (Figure 2 O). In the hMSC-implanted
hemisphere, there was a progressive increase in BrdU+ cells from
5 to 15 days post-implantation. In the PBS-injected hemisphere,
there was a small but not significant increase on day 7 in BrdU+
cells. Most importantly, however, there were significantly more
BrdU+ cells in the hMSC-implanted hemisphere than the
contralateral, PBS-injected hemisphere at days 5 (p=0.0421), 7
(p=0.0293), and 15 days (p,0.001). By day 30, the number of
BrdU+ decreased markedly. Implantation of dead hMSCs had no
effect on the number of BrdU
+ cells.
BrdU
+ Cells Underwent Neurogenesis
To determine whether the BrdU
+ cells differentiated, sections
were co-labeled with markers of differentiation. At 7 days post-
implantation, a small number of the BrdU
+ cells co-labeled with
nestin (Figure 3 A, inset images). By 30 days post-implantation,
there was an apparent increase in BrdU
+ cells co-labeled with
Figure 3. hMSC implantation recruited neuronal cells and induced neurogenesis. There was a slight increase in Nestin
+ NPCs to the site of
the graft (A) compared to the PBS injection (D) at 7 days post-implantation. Many of these recruited Nestin
+ NPCs remained proximal to the graft until
30 days (G compared to J). There was also an influx of NeuN
+ neurons (B) and, to a lesser extent, bIII tubulin
+ neurons (C) to the hMSC graft
compared to the PBS injection (E,F) at 7 days. At 30 days post-implantation there were still more NeuN
+ (H) neurons and an overwhelming increase in
the number of bIII tubulin
+ (I) neurons at the site of the graft compared to the PBS-injected, contralateral hemisphere (K,L). Some BrdU
+ cells co-
labeled with Nestin at 7 days (inset image A) and 30 days (inset image G) post-implantation. A few BrdU
+ cells were NeuN+ at 7 days post-
implantation (inset image B). This number had increased by 30 days post-implantation (inset image H). No BrdU+ cells had matured into bIII tubulin
+
neurons at 7 days post-transplantation (inset image C). By 30 days, many BrdU
+ cells did co-express bIII tubulin (inset image I). Squares demarcate
location of high magnification inset. Scale bar=50 mm. Arrows=co-labeled cells, arrowheads=single labeled cells.
doi:10.1371/journal.pone.0009347.g003
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or without processes (Figure 3 G, inset images). Also, at 7 days
post-implantation, many BrdU
+ cells co-labeled with NeuN
(Figure 3 B, inset images). By 30 days post-implantation,
BrdU
+/NeuN
+ cells were present but most of the BrdU
+ cells
still did not express NeuN (Figure 3 H, inset images). By 30 days
post-implantation, some BrdU
+ cells expressed bIII tubulin
(Figure 3 I, inset images). Therefore, a subset of BrdU
+ cells
differentiated into neurons expressing NeuN and bIII tubulin
within the first 30 days post-implantation. Also, confocal imaging
of sections demonstrated that a fraction of the BrdU
+ cells were
present as astrocytes and even less as microglia/macrophages
(Figure S2). These results suggest that after MSC implantation,
BrdU+ cells have the ability to differentiate into neurons and
neural progenitor cells within the first 7 days. However,
neurogenesis did not appear to be the primary method for repair.
Grafting hMSCs Appeared to Recruit Pre-Existing
Neuronal Cells to the Striatum of HD Mice
In addition to the BrdU
+ cells that underwent neurogenesis into
neural cells, there was also an increase in the number of BrdU
negative cells that were nestin
+, NeuN
+, and bIII tubulin
+ in the
hMSC-implanted hemisphere compared to the PBS-injected
hemisphere. At low magnification at 7 days post-implantation,
there was a slight increase in the number of Nestin
+ cells in the
hMSC-implanted hemisphere when compared to the contralater-
al, PBS-injected hemisphere (Figure 3 A, D). By 30 days post-
implantation, there was a considerable increase in the number of
nestin
+ cells in the hMSC-implanted striatum compared to the
PBS-injected, contralateral hemisphere (Figure 3 G, J). There was
also an increase in the overall number of neurons in the HD
striatum after hMSC implantation compared to the PBS-injected
control when assessed by NeuN staining at 7 (Figure 3 B, E) and 30
days (Figure 3 H, K). At 7 days post-implantation, there was a
slight increase in bIII tubulin+ neurons (Figure 3 C, F). However,
by 30 days, the relative number of bIII tubulin+ neurons in the
MSC-implanted compared to the PBS-injected hemisphere had
increased substantially (Figure 3 I, L). The results indicated either
that some neural stem cells whose proliferation was stimulated by
the hMSCs were not labeled by BrdU, the hMSCs recruited other
progenitor cells the striatum in the HD mice, or hMSC
implantation was neuroprotective and increased survival of pre-
existing, endogenous striatal neurons. There was no apparent
increase in astrocytes, microglia, and macrophages an observation
consistent with the fact that the mice were immunosuppressed
(Figure S3).
Grafting hMSCs in the HD Mouse Striatum Increased
Neurotrophin Signaling
Assays for FGF-2 signaling indicated a substantial increase in
the striatum at 7 days post-implantation when compared to the
contralateral, PBS-injected hemisphere (Figure 4 A, E) and a
further increase by 30 days post-implantation, especially sur-
rounding the SVZ (Figure 4 I, M). CNTF was not increased at 7
days post-implantation (Figure 4B, F) but there was an increase in
the striatum proximal to the SVZ 30 days post-implantation
(Figure 4J, N). VEGF signaling was increased at 7 days post-
hMSC implantation (Figure 4 C, G), and the increase persisted at
30 days in the areas surrounding the original location of the hMSC
graft as well as in the SVZ whereas no VEGF signaling was
detected in the contralateral, PBS injected-hemisphere (Figure 4
K, O). NGF signaling was similarly increased in the striatum at 7
days after hMSC implantation (Figure 4D, H) but only slightly
increased in the SVZ at 30 days (Figure 4L, P). Therefore, hMSC
implantation primarily increased FGF-2 and VEGF signaling at 7
days post-implantation, with increased signaling of FGF-2, CNTF,
and VEGF by 30 days post-implantation.
hMSC Decreased Atrophy of the Striatal Volume in HD
Mice
To assess the effects of hMSCs on HD pathophysiology, hMSCs
were implanted into one hemisphere of the striatum and PBS
injected into the contralateral striatum in 2-month old HD mice.
One month post-implantation, the hMSC-implanted striatum
appeared larger than the contralateral, PBS-injected striatum
(Figure 5 Ai–Av). This effect was most noticeable in the rostral
striatum, close to the implantation site, but was studied throughout
300 mm of the striatum. There were no apparent differences in the
contralateral hemispheres of the striatum in wildtype mice
(Figure 5 Bi–Bv). Total striatal volume of each experimental and
control hemisphere was quantified using stereology. The size of
the striatum in wildtype mice was approximately 7610
9 mm
3 and
is significantly smaller in HD mice (approximately 5.3610
9 mm
3).
The MSC-implanted striatum was significantly larger than the
contralateral, PBS-injected hemisphere (approximately
6.3610
9 mm
3, Figure 5C) in 3-month old HD mice. The HD,
PBS-injected hemisphere was significantly smaller that the wild-
type control hemispheres, but the HD, MSC-implanted hemi-
sphere was not. Therefore, MSC implantation significantly
decreased atrophy of the striatum.
Discussion
This study tested the hypothesis that hMSCs are neurogenic in
the striatum of HD mice by increasing the endogenous cell
response. Previous reports demonstrated that hMSCs disappeared
through necrosis or apoptosis in 5 to 15 days post-implantation
into the dentate gyrus of the hippocampus [30]or wildtype adult
mice [31], and rat MSCs disappeared at about the same rate after
implantation into the striatum of adult rats [32]. A similar rate of
disappearance was observed here after implantation of hMSCs
into the striatum of adult HD mice. Therefore there was little
opportunity for the cells to replace neuronal cells that are lost in
HD. Instead, the cells stimulated proliferation and differentiation
of endogenous neural cells as indicated by the BrdU labeling
experiments. There was also an increase in bIII tubulin
+ neurons
in the striatum that were not BrdU-labeled, an observation
suggesting either that there was recruitment of non-stem cells to
become neurons, increased neuronal survival or pre-existing
neurons, or some neural stem cells escaped labeling with BrdU.
The increase in neurogenesis may in itself account for the
decreased atrophy of the striatum in the treated HD mice
compared to PBS injected controls (Figure 5). However, the
hMSCs may also have exerted a neuroprotective effect as was
observed in a mouse model for transient cerebral ischemia [31].
Both the increased neurogenesis and any neuroprotective effects
were probably exerted through the increase in expression of FGF-
2, CNTF, VEGF, and NGF. The increases in FGF-2, CNTF and
VEGF persisted for at least 30 days, long after no human cells
were detectable. Therefore the transient presence of the hMSCs
must have stimulated prolonged expression of neurotrophins by
endogenous neural cells in the HD brain. Similar effects were
observed after implantation of hMSCs into the dentate gyrus of
wildtype, adult mice [30] and of adult mice following transient
cerebral ischemia [31]. The results here are consistent with the
observation that implantation of autologous bone marrow stromal
cells produced improvement in neurological defects in HD mice,
hMSC Graft in Huntington Mice
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The present study is not focused on clinical improvement in
treated HD mice but the neurological consequence of an hMSC
graft in HD mice; however, a more rigorous study to determine
the age of treatment and variability in the phenotype is critical.
The improvement in neurogenesis and striatal volume observed
in the HD mice supports previous suggestions that therapy with
hMSCs might be effective in CNS diseases such as HD. However,
a number of further questions need to be resolved such as
appropriate time of the therapy and optimal doses. For example,
by simply advancing the surgery by 2 weeks to 6 week-old mice,
MSC implantation no longer had a significant effect on striatal
volume (data not shown). Administration of MSCs may or may not
have long-term benefits, since the endogenous neural cells that
undergo neurogenesis contain the mutated gene. However, the
hMSCs might reset the time clock for development of the disease
phenotype. Observations in models for stroke suggest that
intravenous administration of MSCs or conditioned medium from
MSCs can be effective [27,29]. Therefore repeated administration
of either the cells or soluble factors produced by the cells may be
feasible.
Conclusions
We have demonstrated that hMSCs affect endogenous cells in
the striatum of HD mice by increasing cell proliferation, neuronal
differentiation, and neuronal cell recruitment. Furthermore,
implantation of hMSCs into the striatum of HD mice prevented
striatal atrophy associated with HD. We have documented specific
cellular changes in the HD striatum after hMSC implantation.
hMSCs are isolated from the bone marrow and, therefore, are
readily available for potential therapy or treatment. The results
therefore suggested that neural implantation of hMSCs may be of
benefit in HD but a number of parameters of dose, treatment
schedule, and route of administration need to be optimized.
Figure 4. hMSC implantation increased neurotrophic factor signaling. There was a substantial increase in FGF-2 signaling in the hMSC-
implanted hemisphere (A, I) compared to the contralateral, PBS-injected hemisphere (E, M) at 7 and 30 days post-implantation. There was no increase
in CNTF signaling at 7 days post-implantation (B) compared to the PBS-injected hemisphere (F) although a slight increase was detected by 30 days
post-implantation (J compared to N). There was an increase in VEGF signaling in the hMSC-implanted hemisphere at both 7 (C) and 30 (K) days post-
implantation compared to the PBS-injected hemisphere (G,O). NGF signaling appeared to be increased similarly in both the hMSC- and the PBS-
injected hemispheres 7 days post-implantation (D,H). By 30 days post-implantation, NGF was still slightly increased in the hMSC-implanted
hemisphere (L) compared to the contralateral, PBS-injected hemisphere (P). Scale bar=50 mm.
doi:10.1371/journal.pone.0009347.g004
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Cell Culture
Frozen vials of extensively characterized preparation of hMSCs
from normal healthy donors were obtained from the Tulane
Center for the Preparation and Distribution of Adult Stem Cells
(http://www.som.tulane.edu/gene_therapy/distribute.shtml) un-
der an IRB approved protocol and expanded as described
previously [34]. In brief, vials of passage 1 hMSCs (about 1610
6
cells) plated in 15 cm-diameter dishes in complete hMSC medium
[a-MEM (GIBCO/BRL, Grand Island, NY); 20% pre-screened
FBS (Atlanta Biologicals, Norcross, GA); 100 units/ml penicillin;
100 mg/mL streptomycin; and 2 mM L-glutamine (all from
GIBCO/BRL)]. After 24 h, the viable adherent cells were washed
with phosphate buffered saline (PBS, pH 7.2) and lifted with
0.25% trypsin/1 mM EDTA at 37uC for about 5 min [11] to
recover viable cells. The cells were replated at 50 to100 viable cells
per cm
2 in hMSC medium, incubated with a change of medium
every 3 or 4 days for 7 days until reaching about 70% confluent,
and lifted with trypsin/EDTA. The epitope profile of cells was:
Negative for hematopoietic markers (CD34, CD36, CD117 and
CD45), and positive for CD29 (95%), CD44 (.93%), CD49c
(99%), CD49f (.70%), CD59 (.99%), CD90 (.99%), CD105
(.99%) and CD166 (.99%). For transplantation, the cells were
washed with PBS, centrifuged, and re-suspended in PBS at
25,000 cells/mL. To create Green Fluorescent Protein (GFP)-
hMSCs, GFP lentivirus with an ubiquitin promoter [35] and
polybrene were added to the culture media for 24 hours. At least
95% of the hMSCs were GFP+. GFP-hMSCs were re-plated post-
surgery to confirm viability (Figure S4).
Stereotactic Surgery
All protocols involving animal care and handling were approved
by Emory University’s Institutional Animal Care and Use
Committee. N171-82Q (Jackson Laboratories, Bar Harbor,
Maine) 8-week old mice were used for stereotactic surgery. They
were immunosuppressed with 10 mg/kg cyclosporine A adminis-
tration subcutaneously daily for 3 days prior to and 15 days after
surgery. During Cyclosporine A treatment, mice were housed in
sterile cages with sterile food and water. After pre-treatment with
0.04 mg/kg Atropine, they were anesthetized using 90.0 mg/mL
ketamine and 9.1 mg/mL xylazine intramuscularly. The cranium
was exposed and 4 mL of hMSC suspension in PBS (25,000 cells/
mL) were infused at a rate of 0.5 mL/min at: +0.74 anterior/
posterior, +/21.5 medial/lateral, 22.5 dorsal/ventral relative to
Bregma [36] into the right striatum. The dwell time was 5 min.
The same volume of PBS was injected at the same rate in the left
hemisphere. The wound was closed using Vetbond (Fisher
Scientific, Inc.) and mice were administered 2.5 mg/kg Flunixin
for recovery. For labeling of stem cells, 50 mg/kg bromodeoxy-
uridine (BrdU) neutralized in PBS with 0.007N NaOH was
administered intraperitoneally at the time of surgery and at
12 hour intervals for 7 days.
Perfusion and Brain Tissue Processing
All protocols involving animal care and handling were approved
by Emory University’s Institutional Animal Care and Use
Committee. Mice were euthanized with avertin intraperitoneally,
they were perfused through the left ventricle with ice-cold PBS
followed by 4% paraformaldehyde. The brains removed and post-
fixed in 4% paraformaldehyde overnight at 4uC, transferred to
fresh 30% sucrose for 2 days and then frozen with 2-methylbutane.
Sections were cut at 40–50 mm using a cryostat.
Figure 5. hMSC implantation decreased striatal atrophy in HD
mice. Serial sections throughout the striatum were used for striatal
volume analysis. Serial sections of the striatum are outlined in both HD
mice receiving MSCs or PBS (Ai–Av) and control WT mice (Bi–Bv). There
was an apparent increase in striatal volume after MSC implantation at 8
weeks compared to the contralateral, PBS injected hemisphere (Ai–Av).
There was no apparent difference in the size of the striatum in the
opposite hemispheres in WT mice (Bi–Bv). Scale bar=1 mm. (C)
Stereological analysis at 1 month post-implantation revealed a
significant increase in striatal volume after hMSC implantation
compared to PBS injection (n=526; *). The PBS-injected striatum was
significantly smaller than both the MSC-implanted (a) and PBS WT
control striatum (b). There was no difference between the two
hemispheres in the WT control group. *, a, and b denote p,0.05 by
ANOVA with Holms-Sidak post-hoc analysis.
doi:10.1371/journal.pone.0009347.g005
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Sections requiring detection of bromodeoxyuridine (BrdU) were
first pretreated with 30 min in 2N Hydrochloric acid at 37uC
followed by 15 min in borate buffer at room temperature. Sections
were blocked using 5% serum in Triton-X 100. Incubation in the
primary antibody was overnight at 4uC and in the secondary
antibody was 1 hour at room temperature. Primary antibodies used
include: BrdU (Abcam Inc, Cambridge, ME), Nestin (Chemicon
International, Temecula, CA), neuronal nuclei (Chemicon Inter-
national), bIII Tubulin (Chemicon International), glial fibrillary
acidic protein (Chemicon International), Iba1 (Wako Pure Chem-
ical Industries, Ltd, Richmond, VA), ciliary neurotrophic factor
(Santa Cruz Biotechnology, Inc.), fibroblast growth factor-2 (Santa
Cruz Biotechnology, Inc.), nerve growth factor (Santa Cruz
Biotechnology, Inc.), vascular endothelial growth factor (Chemicon
International). Sections were mounted and coverslipped using
Vectashield (Vector Laboratories, Inc, Burlingame, CA).
Hematoxylin and Eosin Stain
Sections were mounted and allowed to adhere to the slide
overnight. Sections were incubated in Hematoxylin for 10 seconds
and Eosin for 5 seconds. Sections were rehydrated with water and
mounted with aqueous media.
Microscopy
All confocal images were taken using the Zeiss LSM 510 Meta
Confocal and corresponding software.
Stereology
All sections to be used forstereology were sectioned at 50 mm and
examined with a spinning disc confocal microscope. Stereo
Investigator (Microbrightfield Bioscience, Williston, VT) was used
to count cells. Cells werecountedin every sixth section. Each mouse
for stereological assessment received an hMSC graft in the right
hemisphere and a PBS injection in the left hemisphere. The total
number of GFP+ was counted in every sixth section. No ratio was
needed for the MSC graft volume estimates because the entire size
ofthegraft wascalculated.Theentirestriatum was outlined inevery
sixth section and randomly sampled to count for BrdU+ cells. For
analysis, both the total number of BrdU+ cells in each hemisphere
as well as the ratio of BrdU+ cells in the hMSC-implanted
hemisphere to those in the PBS-injected hemisphere was calculated
to reduce potential differences in data collection between subjects.
To quantify the volume of the striatum, the area of the entire
striatum was measured in every third section. Based on the area in
each section, the number of sections, plus the thickness of each
section, the total volume per hemisphere was calculated. The ratio
ofthevolume inthe MSC-implantedhemispheretothat ofthe PBS-
injected hemisphere was also determined.
Statistics
A one-way ANOVA was used to determine if any of the groups
were significantly different from the rest. A One-way RM
ANOVA was also used to determine any differences within each
group. The post-hoc test used was the Holms-Sidak test.
Supporting Information
Figure S1 Confocal microscopy of GFP-hMSCs in vivo.H i g h
magnification confocal microscopy confirmed GFP-hMSCs did not
divide in vivo. Intact GFP-hMSCs did not label (arrows) with BrdU
at 1 day (A–D), 3 days (E–H), or 5 days (I–L). As hMSCs died, some
GFP-hMSC remnants were phagocytosed by surrounding cells
(arrowheads),includingBrdU
+cellsat5 days(I–L),7 days(M–P),15
days (Q–T), and 30 days (U–X). Scale bar=40 mm.
Found at: doi:10.1371/journal.pone.0009347.s001 (8.78 MB TIF)
Figure S2 BrdU
+ cells underwent gliogenesis. (A) A few BrdU
+
cells differentiated into astrocytes by 7 days post-implantation. (B)
By 30 days, many BrdU
+ cells underwent gliogenesis into mature
astrocytes with long, elaborate processes. A few BrdU
+ cells had
differentiated into mature microglia/macrophages at 7 (C) and 30
days (D) post-implantation. Arrows=co-label examples. Arro-
wheads=single-label examples. Scale bar=40 mm.
Found at: doi:10.1371/journal.pone.0009347.s002 (10.19 MB
TIF)
Figure S3 Grafting hMSCs did not recruit pre-existing,
endogenous glial cells. There was no difference in the number of
GFAP
+ astrocytes in the hMSC-implanted hemisphere (A, C)
compared to the PBS-injected hemisphere (E, G) at 7 or 30 days
post-implantation. There was also no difference in the number of
Iba1
+ microglia/macrophages at the site of the hMSC graft (B, D)
compared to the PBS injection (F, H) at 7 or 30 days post-
implantation. Scale bar=50 mm.
Found at: doi:10.1371/journal.pone.0009347.s003 (6.21 MB TIF)
Figure S4 Morphology of hMSCs. hMSCs were plated at
100 cells/cm2 and grown to 70% confluency before harvesting for
surgery (A). Cells were infected with GFP during their post-thaw,
recovery phase. DIC images reveal the typical morphology of
MSCs and GFP fluorescence microscopy showed almost 100%
expression. Cells were re-plated immediately following surgery and
still proved to be viable (B).
Found at: doi:10.1371/journal.pone.0009347.s004 (3.41 MB TIF)
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